Tocilizumab Initiation based on Indicator in Patients Infected by Coronavirus-19 to Prevent Intubation
DOI:
https://doi.org/10.3889/oamjms.2023.10147Keywords:
COVID-19, Tocilizumab, Acute respiratory distress syndrome, IntubationAbstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has created severe medical and economic consequences worldwide since 2019. Tocilizumab is one of the therapies considered capable of improving the condition of patients with COVID-19. However, there is not much information about the best time to give tocilizumab.
METHODS: This was an analytical study with a retrospective cohort design, using the data of 125 patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with signs of acute respiratory distress syndrome in Dr. Moewardi Hospital, Surakarta, from March to August 2020. We analyzed various available clinical data to see which factors into clinical improvement with tocilizumab therapy.
RESULTS: Most patients showed clinical improvement after administration of tocilizumab. During the follow-up period, 21 patients died despite tocilizumab therapy. Significant risk factors associated with the need for intubation were heart rate, neutrophil, lymphocyte, pH, PaCO2, and PO2. The most influential variable on the need for intubation without being associated with other risk factors was PaO2 (p = 0.003, Confidence Intervals 95%).
CONCLUSIONS: Tocilizumab has a role in treating patients infected by SARS-CoV-2, preventing the need for intubation when given to patients in good saturation condition with oxygen supplementation without positive pressure (PaO2 >65mmHg; SpO2 >93%).
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Johns Hopkins Coronavirus Resource Center. COVID-19 Map. Baltimore: Johns Hopkins University of Medicine; 2022.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. https://doi.org/10.1007/s00281-017-0629-x PMid:28466096 DOI: https://doi.org/10.1007/s00281-017-0629-x
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1-9. https://doi.org/10.1002/rmv.2141 PMid:32845568 DOI: https://doi.org/10.1002/rmv.2141
Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21-42. https://doi.org/10.1007/s40744-018-0102-x PMid:29502236 DOI: https://doi.org/10.1007/s40744-018-0102-x
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954 PMid:32234467 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105954
Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A multicentre cohort study. Clin Microbiol Infect. 2021;27(2):238-43. https://doi.org/10.1016/j.cmi.2020.09.021 PMid:32979572 DOI: https://doi.org/10.1016/j.cmi.2020.09.021
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41-51. https://doi.org/10.1001/jamainternmed.2020.6252 PMid:33080002 DOI: https://doi.org/10.1001/jamainternmed.2020.6252
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-44. https://doi.org/10.1056/NEJMoa2028836 PMid:33085857 DOI: https://doi.org/10.1056/NEJMoa2028836
Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3):106103. https://doi.org/10.1016/j.ijantimicag.2020.106103 PMid:32712333 DOI: https://doi.org/10.1016/j.ijantimicag.2020.106103
Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020;24(1):589. https://doi.org/10.1186/s13054-020-03306-6 PMid:32993751 DOI: https://doi.org/10.1186/s13054-020-03306-6
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients With COVID-19. Clin Infect Dis. 2021;73(2):e445-54. https://doi.org/10.1093/cid/ciaa954 PMid:32651997 DOI: https://doi.org/10.1093/cid/ciaa954
Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study. Lancet Rheumatol. 2020;2(10):e603-12. https://doi.org/10.1016/S2665-9913(20)30277-0 PMid:32838323 DOI: https://doi.org/10.1016/S2665-9913(20)30277-0
Vu CA, DeRonde KJ, Vega AD, Maxam M, Holt G, Natori Y, et al. Effects of Tocilizumab in COVID-19 patients: A cohort study. BMC Infect Dis. 2020;20(1):964. https://doi.org/10.1186/s12879-020-05701-4 PMid:33353546 DOI: https://doi.org/10.1186/s12879-020-05701-4
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64. https://doi.org/10.1182/blood-2008-05-155846 PMid:18784373 DOI: https://doi.org/10.1182/blood-2008-05-155846
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-8. https://doi.org/10.1002/jmv.25801 PMid:32253759 DOI: https://doi.org/10.1002/jmv.25801
Putra NP, Listyoko AS, Christanto A. PaO2, SaO2, dan rasio PaO2/FiO2 sebagai prediktor derajat keparahan pasien COVID-19 rawat inap. J Indo Med Assoc. 2020;70(12):253-9. DOI: https://doi.org/10.47830/jinma-vol.70.12-2020-326
Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158(1):195-205. https://doi.org/10.1016/j.chest.2020.03.032 PMid:32224074 DOI: https://doi.org/10.1016/j.chest.2020.03.032
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585 PMid:32031570 DOI: https://doi.org/10.1001/jama.2020.1585
Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res. 2020;21(1):198. https://doi.org/10.1186/s12931-020-01462-5 PMid:32723327 DOI: https://doi.org/10.1186/s12931-020-01462-5
Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: A multicentre prospective observational study. Lancet Respir Med. 2020;8(12):1201-8. https://doi.org/10.1016/S2213-2600(20)30370-2 PMid:32861276 DOI: https://doi.org/10.1016/S2213-2600(20)30370-2
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Septian Adi Permana, Adhrie Sugiarto, Sidharta Kusuma Manggala, Muhammad Husni Thamrin, Purwoko Purwoko, Handayu Ganitafuri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
